CardiaCare to partner with Dr. Reddy’s Laboratories in India

CardiaCare recently announced it signed a strategic licensing agreement with Dr. Reddy’s Laboratories to further develop CardiaCare’s wearable atrial fibrillation treatment device.

Through the agreement, Dr. Reddy’s Laboratories will lead necessary clinical studies for CardiaCare to receive regulatory clearance in India.

CardiaCare is developing a non-invasive, personalized neuromodulation wearable for atrial fibrillation treatment. It will receive undisclosed upfront and royalty payments, while Dr. Reddy’s will manage commercialization and distribution in India.

The agreement will make India the first market to offer a home-care digital therapeutic for AFib patients, according to the news release posted Dec. 15. Headquartered in Hyderabad, Dr. Reddy’s had $2.8 billion in revenue in its most recent fiscal year. It’s one of a number of major pharmaceutical companies based out of India.

“We look forward to working closely with the Dr. Reddy’s Laboratories team to help improve patient outcomes worldwide. We will continue to execute on our clinical development plans in other regions for this initial as well as additional indications in our pipeline,” CardiaCare founder and chief scientific officer Amos Ziv said in the news release.

CardiaCare’s wearable device uses a closed-loop approach to integrate therapy and monitoring. It uses AI-based ECG analysis algorithms to allow optimized and personalized AFib treatment. Initial clinical data has suggested that the therapeutic approach has both acute and cumulative effects and decreases atrial fibrillation precursors and overall disease burden, according to the company.

“Partnering with Dr. Reddy’s Laboratories accelerates CardiaCare’s evidence generation and commercialization activity, externally validating the potential of our game-changing technology for the treatment of atrial fibrillation. Our device enables safe, drug-free, at-home treatment, that has been shown to increase AF treatment efficacy and decrease costs. Our closed-loop approach integrating therapy and monitoring optimizes and personalizes care, providing clinicians and patients better AF management,” CardiaCare CEO Ofer Halbreich said. MassDevice